Cargando…

HER2 expression status in diverse cancers: review of results from 37,992 patients

Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been reported in other malignancies, previous studies generally focused on one cancer type, making it challenging to compare HER2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Min, Schwaederle, Maria, Arguello, David, Millis, Sherri Z., Gatalica, Zoran, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368842/ https://www.ncbi.nlm.nih.gov/pubmed/25712293 http://dx.doi.org/10.1007/s10555-015-9552-6

Ejemplares similares

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
por: Helsten, Teresa, et al.
Publicado: (2015)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
por: Gatalica, Zoran, et al.
Publicado: (2014)

Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities
por: Millis, Sherri Z., et al.
Publicado: (2018)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
por: Jardim, Denis L., et al.
Publicado: (2020)

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics
por: Jardim, Denis L., et al.
Publicado: (2021)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Cyclin alterations in diverse cancers: outcome and co-amplification network
por: Schwaederlé, Maria, et al.
Publicado: (2014)

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types
por: Schwaederle, Maria, et al.
Publicado: (2015)

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
por: Kato, Shumei, et al.
Publicado: (2015)

Targeting HER2 expression in cancer: New drugs and new indications
por: Vranić, Semir, et al.
Publicado: (2021)

Correlation of Doppler parameters with renal pathology: A study of 992 patients
por: CHEN, QINKAI, et al.
Publicado: (2014)

The Melaka Hospital cataract complications study analysis of 12,992 eyes
por: Thevi, Thanigasalam, et al.
Publicado: (2017)

Correction to Lancet Glob Health 2016; 5: e992–1003
Publicado: (2017)

Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
por: Movva, Sujana, et al.
Publicado: (2015)

Mild Parkinsonian Signs in the Elderly – Is There an Association with PD? Crossectional Findings in 992 Individuals
por: Lerche, Stefanie, et al.
Publicado: (2014)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Influence of Sandblasting and Chemical Etching on Titanium 99.2–Dental Porcelain Bond Strength
por: Lubas, Malgorzata, et al.
Publicado: (2021)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
por: Vanderwalde, Ari, et al.
Publicado: (2018)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
por: Ang, Celina, et al.
Publicado: (2019)

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis
por: Endres, Dominique, et al.
Publicado: (2020)

Early Emergence and Dispersal of Delta SARS-CoV-2 Lineage AY.99.2 in Brazil
por: Romano, Camila Malta, et al.
Publicado: (2022)

Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
por: Cimic, Adela, et al.
Publicado: (2021)

992. Rethinking the 28-day HIV nPEP Dispensing Practice: A Pediatric ID Clinic Analysis
por: Zhang, David, et al.
Publicado: (2020)

HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome
por: Skenderi, Faruk, et al.
Publicado: (2022)

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report
por: Mohammed, Anwarullah, et al.
Publicado: (2015)

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer
por: Schwaederle, Maria, et al.
Publicado: (2015)

Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy
por: Moon, Young-Jin, et al.
Publicado: (2018)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients
por: Schwaederle, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8c0thkjqb5pq2q9sbmbgdknhfl